Medical AI Alliance
← Company Index
Medical AIKONEX 3119605 approvals

InterRoid Co., Ltd.

Official website

Provides the SeiRen Suite call automation solution built on an integrated STT, LLM, and TTS voice AI platform.

As of 2026-10-11, InterRoid Co., Ltd. has 5 Korean MFDS device approvals on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2012 and listed on KONEX in 2022, InterRoid specializes in Voice AI Agent technology. Based on an integrated platform combining speech-to-text (STT), large language models (LLM), and text-to-speech (TTS), it offers the SeiRen Suite call automation solution and the RAG-based chatbot builder Seiren Chatbot. Its STT engine is trained on over 25,000 hours of data, achieving a Character Error Rate (CER) of about 3.5%, and it also runs AI modeling consulting, an LLMOps platform, and AI Vision solutions.

Products & technology

  • SeiRen SuiteVoice call automation combining STT, chatbot, and TTS
  • Seiren ChatbotRAG+LLM+dialogue management chatbot builder platform

Regulatory approvals

data.go.kr

5 Korean MFDS device approvals · 2023–2024

  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2024-02-06
    Product approval · Class 3체외 제허 24-94 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-01-30
    Product approval · Class 4체외 제허 24-75 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, molecular diagnostics2024-01-30
    Product approval · Class 4체외 제허 24-74 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-12-27
    Product approval · Class 3체외 제허 23-1181 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2023-07-28
    Product approval · Class 3체외 제허 23-807 호

R&D and key agreements

Source: DART corporate disclosure

STT 엔진 고도화 · STT engine trained on over 25,000 hours of data achieving a Character Error Rate of about 3.5%

Key disclosures

KRX KIND via OpenDART

Patents

KIPRIS · applicant-matched
Show 56 more patents

AI reads

MAA server logs · IP-verified
21
Times AI engines pulled InterRoid Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

21
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

1
live 0
Last 7 days
12
live 0
Last 30 days
21
live 0
All time
  • OpenAIOAI-SearchBot12
  • PerplexityPerplexityBot3
  • MicrosoftBingbot2
  • GoogleGoogleOther2
  • AnthropicClaudeBot2

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for InterRoid Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsMedical AI

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

RollingStone Co., Ltd.2 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

BIONEERCORPORATION2 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

GC Medical Science Corporation2 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

SEEGENE, INC.2 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

Genesystem Co., Ltd2 shared

Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.

CG Invites Co., Ltd.1 shared

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

Median Diagnostics Inc.1 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

NGeneBio Co., Ltd.1 shared

KOSDAQ-listed precision-diagnostics company manufacturing genomic diagnostic reagents and developing related software.

iNtRON Biotechnology, Inc.1 shared

Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

HLB PANAGENE Co., LTD.1 shared

Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition